Abstract
While cases of uveal melanoma are relatively rare overall, it remains the most common intraocular cancer in adults and has a 10-year fatality rate of approximately 50% in metastatic patients with no effective treatment options. Mutations in BAP1, a tumor suppressor gene, have been previously found to be associated with the onset of metastasis in uveal melanoma patients. In this study, I utilize a weakly supervised deep learning-based pipeline in order to analyze whole slide images (WSIs) of uveal melanoma patients in conjunction with slide-level labels regarding the presence of BAP1 mutations. I demonstrate that there is a strong relationship between BAP1 mutations and physical tumor development in uveal melanoma and that my model is able to predict such relationships with an optimized mean test AUC of 0.86. My findings demonstrate that deep learning models are able to accurately predict patient-specific genotypic characteristics in uveal melanoma. Once integrated into and adapted to existing non-invasive ocular scanner technologies, my model would assist healthcare professionals in understanding the specific genetic profiles of their patients and provide more personalized treatment options in a safe, efficient manner, thus resulting in improved treatment outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for any part of this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All uveal melanoma WSI data was obtained from The Cancer Genome Atlas, a program developed by the National Cancer Institute and the National Human Genome Research Institute that offers a wide array of clinical and biomedical data for 33 types of cancer free of charge to the general public.
